Phase II Trial of Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Next Previous
Trial Profile

Phase II Trial of Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms MUTATION2

    • Most Recent Events

    • 12 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top